SCHEDULE 13D/A: Enzo Biochem's Major Shareholder Commits to Merger Agreement with Bethpage Parent

Bradley L. Radoff, a significant shareholder and director of Enzo Biochem Inc., has formally agreed to support the company's merger with Bethpage Parent, Inc. by committing his substantial shareholdings.

Summary

• Bradley L. Radoff and the Radoff Family Foundation collectively beneficially own 4,820,882 shares of Enzo Biochem Inc., representing approximately 9.2% of the 52,432,129 outstanding shares as of June 19, 2025.
• Enzo Biochem Inc. entered into an Agreement and Plan of Merger with Bethpage Parent, Inc. and Bethpage Merger Sub, Inc. on June 23, 2025, which will result in Enzo Biochem becoming a wholly-owned subsidiary of Bethpage Parent.
• Concurrently with the merger agreement, Bradley L. Radoff, in his capacity as a shareholder, signed a Voting and Support Agreement, committing to vote all his shares in favor of the Merger and against any alternative transaction proposal.
• Under the Voting and Support Agreement, Mr. Radoff also agreed not to transfer any shares (subject to certain exceptions), grant any proxies or powers of attorney, or exercise any dissenters' rights with respect to the Merger.
• The Radoff Family Foundation purchased 430,000 shares for approximately $1,427,845 using working capital.
• Mr. Radoff purchased 4,155,600 shares for approximately $13,026,662 using personal funds.
• Mr. Radoff has been awarded 378,179 restricted stock units (RSUs) as a director, with 235,282 having vested as of the filing date, and the remaining 142,897 RSUs vesting upon the earlier of January 16, 2026, or a change of control event.

Sentiment

Score: 6

Explanation: The document reports a significant shareholder's commitment to a merger agreement, which generally signals a positive strategic direction for the company, although specific financial terms of the merger are not disclosed in this filing.

Positives

• A significant shareholder, Bradley L. Radoff, has committed to supporting the proposed merger, indicating alignment with the company's strategic direction and potentially streamlining the merger approval process.
• The merger agreement with Bethpage Parent, Inc. could provide a clear strategic path for Enzo Biochem Inc., potentially offering liquidity or other strategic benefits to shareholders.

Negatives

• The document does not disclose the financial terms of the merger, such as the per-share price, making it impossible to assess the immediate financial impact on shareholders.
• Mr. Radoff's agreement not to exercise dissenters' rights or transfer shares limits his flexibility regarding his significant stake in the company until the merger's outcome.

Risks

• The Voting and Support Agreement, which commits Mr. Radoff's shares to the merger, terminates if the Merger Agreement is validly terminated, potentially leaving the company in an uncertain state if the merger fails.
• The success of the merger is contingent on various factors, and its failure could impact the company's stock price and strategic direction.

Future Outlook

Enzo Biochem Inc. is set to merge with Bethpage Merger Sub, Inc., becoming a wholly-owned subsidiary of Bethpage Parent, Inc., following an agreement entered into on June 23, 2025. This indicates a strategic shift towards integration under new ownership.

Industry Context

The proposed merger of Enzo Biochem Inc. with Bethpage Parent, Inc. reflects a trend of consolidation within the biotechnology and life sciences sectors, where companies seek strategic partnerships or acquisitions to enhance market position, expand capabilities, or achieve economies of scale. Such transactions are common as companies navigate competitive landscapes and evolving market demands.

Corporate Governance

Related Party Transactions

• Bradley L. Radoff, a director of Enzo Biochem Inc., is also the beneficial owner of shares held by the Radoff Family Foundation, and has been awarded restricted stock units by the Issuer in his capacity as a director.
• The Radoff Family Foundation and Bradley L. Radoff are reporting persons in this filing, detailing their collective beneficial ownership and the source of funds for their share purchases.

Stakeholder Impact

• Shareholders: The merger agreement could lead to a change in ownership and potentially a cash payout or share exchange, depending on the merger terms (not disclosed here). Bradley L. Radoff's commitment to the merger provides certainty for its approval from a significant shareholder.
• Employees: A merger often leads to integration efforts that can impact employee roles, structure, and culture, though specific details are not provided.
• Management: The merger will result in Enzo Biochem becoming a wholly-owned subsidiary, which typically implies changes in the management structure and reporting lines.

Next Steps

• Completion of the merger between Enzo Biochem Inc. and Bethpage Merger Sub, Inc., resulting in Enzo Biochem becoming a wholly-owned subsidiary of Bethpage Parent, Inc.
• Voting by shareholders on the Merger Agreement, with Bradley L. Radoff committed to voting his shares in favor.
• Vesting of Bradley L. Radoff's remaining 142,897 restricted stock units by January 16, 2026, or upon a change of control event.

Key Dates

Keywords

Enzo Biochem Inc., Bethpage Parent Inc., Merger Agreement, Schedule 13D, Voting and Support Agreement, Bradley L. Radoff, Shareholder Agreement, Corporate Acquisition, SEC Filing, Restricted Stock Units